Dendritic Cell Therapy with Neoantigens and Oncoantigens].

We treated 3,164 patients with advanced cancer with dendritic cell therapy between July 2005 and March 2020. The effective rate in patients treated with dendritic cell therapy more than 3 times was 19.0%. Among them, we treated 133 cancer patients with a combination of immune checkpoint inhibitors and dendritic cell therapy between June 2015 and March 2020. The effective rate in these patients was 54.1%. We treated 98 cancer patients with dendritic cell therapy with neoantigens between March 2018 and March 2020. The effective rate in these patients treated with neoantigens was 38.7%. The effective rate in patients treated without neoantigens was 18.3%. Dendritic cell therapy with neoantigens enhanced the effective rate. The effective rate of dendritic cell therapy with both immune checkpoint inhibitors and neoantigens was 60.7%.

Citation

Tsutomu Takeda, Takashi Takeda, Yui Kubota, Akika Kubota, Nobuaki Hattori, Hiroko Takeda, Takeo Hasegawa, Junichi Nakamura, Yuhki Yokoyama, Hirofumi Yamamoto. Dendritic Cell Therapy with Neoantigens and Oncoantigens]. Gan to kagaku ryoho. Cancer & chemotherapy. 2020 Nov;47(11):1621-1623

Mesh Tags

Substances

PMID: 33268740

search → result